In plain language
This is a combination of two appetite-acting medicines: cagrilintide (an amylin agonist) and semaglutide (a GLP-1 agonist). The idea is to target two different satiety pathways at once for greater weight loss. The combination has been studied in human trials with encouraging results, but it is not yet approved as a single product.
What it is explored for
Pairing an amylin agonist with a GLP-1 agonist is an exciting idea, engaging two satiety pathways at once for a potentially stronger effect than either alone. Human trials have reported substantial weight loss, which is why this combination is so closely watched. It is still investigational, however, and its long-term outcomes are not yet established. Here is where interest is concentrated.
- Weight management and appetite support
- Greater weight loss than single agents
- Dual-pathway satiety signaling
- Metabolic and obesity research
- Combination therapy approaches
These are areas of active interest and reported use, not proven outcomes. This peptide carries a moderate (human) rating, see the evidence summary below for how strong the science actually is.
How it works
The combination pairs cagrilintide, a long-acting amylin analog, with semaglutide, a GLP-1 agonist, to engage two complementary appetite pathways.
- Amylin pathway (cagrilintide). Activates amylin receptors that promote satiety and slow gastric emptying.
- GLP-1 pathway (semaglutide). Activates GLP-1 receptors to reduce appetite and enhance glucose-dependent insulin secretion.
- Complementary action. Targeting two satiety mechanisms together is intended to produce greater weight loss than either alone.
The rationale is supported by trial data on each component and on the combination, but the combination remains investigational and its long-term effects are not established.
Evidence summary
The cagrilintide plus semaglutide combination has moderate human evidence. Trials have reported substantial weight loss, in some analyses exceeding either agent alone, and phase 3 studies have been conducted. Because it is not yet approved as a combined product and long-term data are limited, the evidence is moderate.
Reported safety & side effects
Reported side effects in trials have been mainly gastrointestinal (nausea, vomiting), consistent with both components. As an investigational combination, its full safety profile is not yet established.
Frequently asked
Is this combination approved?
No. The cagrilintide plus semaglutide combination (sometimes called CagriSema) is investigational and not FDA-approved as a single product.
Why combine the two?
Cagrilintide acts on the amylin pathway and semaglutide on the GLP-1 pathway. Combining them targets two appetite mechanisms at once, which trials are studying to see whether it produces greater weight loss.
How strong is the evidence?
Human trials are encouraging for weight loss, but the combination is still in development and long-term outcomes are not established, so the evidence is moderate.